Overview
Bristol-Myers Squibb Company, headquartered in the United States, is a global biopharmaceutical firm primarily involved in discovering, developing, and delivering innovative medicines aimed at treating serious diseases. Its main therapeutic areas include oncology, cardiovascular, immunology, and fibrotic diseases. Among its key projects are the development and enhancement of Opdivo and Yervoy, drugs used in cancer treatment, which significantly contribute to the company's revenue stream. Additionally, Bristol-Myers Squibb is actively expanding its portfolio through strategic acquisitions, such as the purchase of Celgene and MyoKardia, which bolster its position in hematology and rare disease treatment, respectively. The company invests heavily in research and development to maintain a pipeline of progressive therapies that address unmet medical needs.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for Bristol-Myers Squibb Company - Equity Right as of June 30, 2025 is 47,704.00 MM.
- The operating income for Bristol-Myers Squibb Company - Equity Right as of June 30, 2025 is 12,637.00 MM.
- The net income for Bristol-Myers Squibb Company - Equity Right as of June 30, 2025 is 5,049.00 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | 47,704.00 | 12,637.00 | 5,049.00 |
| 2025-03-31 | 47,636.00 | 11,084.00 | 5,419.00 |
| 2024-12-31 | 48,300.00 | 9,832.00 | -8,948.00 |
| 2024-09-30 | 47,435.00 | 9,009.00 | -7,258.00 |
| 2024-06-30 | 46,509.00 | 9,011.00 | -6,541.00 |
| 2024-03-31 | 45,534.00 | 8,334.00 | -6,148.00 |
| 2023-12-31 | 45,006.00 | 8,651.00 | 8,025.00 |
| 2023-09-30 | 44,935.00 | 8,472.00 | 8,285.00 |
| 2023-06-30 | 45,187.00 | 8,700.00 | 7,963.00 |
| 2023-03-31 | 45,848.00 | 9,630.00 | 7,311.00 |
| 2022-12-31 | 46,159.00 | 9,141.00 | 6,327.00 |
| 2022-09-30 | 46,738.00 | 10,458.00 | 6,677.00 |
| 2022-06-30 | 47,144.00 | 10,760.00 | 6,617.00 |
| 2022-03-31 | 46,960.00 | 10,627.00 | 6,251.00 |
| 2021-12-31 | 46,385.00 | 8,572.00 | 6,994.00 |
| 2021-09-30 | 45,468.00 | 9,002.00 | -5,405.00 |
| 2021-06-30 | 44,384.00 | 8,251.00 | -5,079.00 |
| 2021-03-31 | 42,810.00 | 7,596.00 | -6,219.00 |
| 2020-12-31 | 42,518.00 | 3,391.00 | -9,015.00 |
| 2020-09-30 | 39,395.00 | 7,845.00 | -44.00 |
| 2020-06-30 |
Income Statement: EPS
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | ||
| 2025-03-31 | 2.67 | 2.67 |
| 2024-12-31 | -4.41 | -4.41 |
| 2024-09-30 | -3.58 | -3.58 |
| 2024-06-30 | -3.22 | -3.22 |
| 2024-03-31 | -3.00 | -3.00 |
| 2023-12-31 | 3.88 | 3.86 |
| 2023-09-30 | 3.97 | 3.94 |
| 2023-06-30 | 3.78 | 3.76 |
| 2023-03-31 | 3.45 | 3.43 |
| 2022-12-31 | 2.97 | 2.95 |
| 2022-09-30 | 3.10 | 3.08 |
| 2022-06-30 | 3.04 | 3.02 |
| 2022-03-31 | 2.84 | 2.82 |
| 2021-12-31 | 3.15 | 3.12 |
| 2021-09-30 | -2.42 | -2.42 |
| 2021-06-30 | -2.26 | -2.26 |
| 2021-03-31 | -2.76 | -2.76 |
| 2020-12-31 | -3.99 | -3.99 |
| 2020-09-30 | -0.02 | -0.02 |
| 2020-06-30 | -0.28 | -0.28 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Bristol-Myers Squibb Company - Equity Right as of June 30, 2025 is 15,901.00 MM.
- The cash from investing activities for Bristol-Myers Squibb Company - Equity Right as of June 30, 2025 is -1,387.00 MM.
- The cash from financing activities for Bristol-Myers Squibb Company - Equity Right as of June 30, 2025 is -8,323.00 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | 15,901.00 | -1,387.00 | -8,323.00 |
| 2025-03-31 | 14,310.00 | -2,233.00 | -10,510.00 |
| 2024-12-31 | 15,190.00 | -21,352.00 | 5,127.00 |
| 2024-09-30 | 15,003.00 | -22,502.00 | 7,736.00 |
| 2024-06-30 | 14,163.00 | -22,693.00 | 6,428.00 |
| 2024-03-31 | 13,724.00 | -21,703.00 | 8,278.00 |
| 2023-12-31 | 13,860.00 | -2,295.00 | -9,416.00 |
| 2023-09-30 | 12,914.00 | 264.00 | -13,629.00 |
| 2023-06-30 | 11,850.00 | -1,407.00 | -13,012.00 |
| 2023-03-31 | 12,224.00 | -1,367.00 | -14,359.00 |
| 2022-12-31 | 13,066.00 | -1,062.00 | -16,962.00 |
| 2022-09-30 | 13,817.00 | -1,874.00 | -17,683.00 |
| 2022-06-30 | 15,396.00 | -769.00 | -14,920.00 |
| 2022-03-31 | 16,195.00 | -300.00 | -14,582.00 |
| 2021-12-31 | 16,207.00 | -538.00 | -16,224.00 |
| 2021-09-30 | 15,505.00 | -12,751.00 | -8,774.00 |
| 2021-06-30 | 12,506.00 | -11,988.00 | -9,581.00 |
| 2021-03-31 | 13,939.00 | -11,612.00 | -7,392.00 |
| 2020-12-31 | 14,052.00 | -10,859.00 | -1,151.00 |
| 2020-09-30 | 12,878.00 | -11,226.00 | -12,311.00 |
| 2020-06-30 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | |||
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2021-09-30 | |||
| 2021-06-30 | |||
| 2021-03-31 | |||
| 2020-12-31 | |||
| 2020-09-30 | |||
| 2020-06-30 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2022-12-31 | ||
| 2022-09-30 | ||
| 2022-06-30 | ||
| 2022-03-31 | ||
| 2021-12-31 | ||
| 2021-09-30 | ||
| 2021-06-30 | ||
| 2021-03-31 | ||
| 2020-12-31 | ||
| 2020-09-30 | ||
| 2020-06-30 |
Management Effectiveness
- The roa for Bristol-Myers Squibb Company - Equity Right as of June 30, 2025 is 0.06.
- The roe for Bristol-Myers Squibb Company - Equity Right as of June 30, 2025 is 0.32.
- The roic for Bristol-Myers Squibb Company - Equity Right as of June 30, 2025 is 0.08.
- The croic for Bristol-Myers Squibb Company - Equity Right as of June 30, 2025 is 0.02.
- The ocroic for Bristol-Myers Squibb Company - Equity Right as of June 30, 2025 is 0.21.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2025-06-30 | 0.06 | 0.32 | 0.08 | 0.02 | 0.21 |
| 2025-03-31 | -0.09 | -0.54 | -0.13 | -0.02 | 0.22 |
| 2024-12-31 | -0.08 | -0.25 | -0.11 | 0.00 | 0.22 |
| 2024-09-30 | -0.07 | -0.23 | -0.09 | -0.03 | 0.20 |
| 2024-06-30 | -0.07 | -0.19 | -0.08 | 0.00 | 0.19 |
| 2024-03-31 | 0.08 | 0.25 | 0.11 | 0.03 | 0.20 |
| 2023-12-31 | 0.12 | -0.01 | 0.19 | ||
| 2023-09-30 | 0.24 | -0.08 | |||
| 2023-06-30 | 0.24 | 0.24 | -0.08 | ||
| 2023-03-31 | 0.23 | 0.22 | -0.11 | ||
| 2022-12-31 | |||||
| 2022-09-30 | 0.18 | 0.20 | |||
| 2022-06-30 | 0.00 | 0.00 | |||
| 2022-03-31 | 0.00 | 0.00 | |||
| 2021-12-31 | 0.00 | 0.00 | |||
| 2021-09-30 | 0.00 | 0.00 | 0.00 | ||
| 2021-06-30 | -0.04 | -0.06 | -0.11 | 0.15 | |
| 2021-03-31 | -0.05 | -0.12 | -0.07 | -0.06 | 0.16 |
| 2020-12-31 | -0.07 | -0.10 | 0.02 | 0.16 | |
| 2020-09-30 | -0.00 | -0.00 | -0.00 | -0.11 | 0.13 |
| 2020-06-30 | -0.01 | -0.03 | -0.01 | -0.08 | 0.13 |
Gross Margins
- The gross margin for Bristol-Myers Squibb Company - Equity Right as of June 30, 2025 is 0.75.
- The net margin for Bristol-Myers Squibb Company - Equity Right as of June 30, 2025 is 0.11.
- The operating margin for Bristol-Myers Squibb Company - Equity Right as of June 30, 2025 is 0.23.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2025-06-30 | 0.75 | 0.11 | 0.23 |
| 2025-03-31 | 0.75 | -0.19 | 0.20 |
| 2024-12-31 | 0.76 | -0.15 | 0.19 |
| 2024-09-30 | 0.76 | -0.14 | 0.19 |
| 2024-06-30 | 0.76 | -0.14 | 0.18 |
| 2024-03-31 | 0.77 | 0.18 | 0.19 |
| 2023-12-31 | 0.77 | 0.18 | 0.19 |
| 2023-09-30 | 0.18 | 0.19 | |
| 2023-06-30 | 0.18 | 0.19 | |
| 2023-03-31 | 0.16 | 0.21 | |
| 2022-12-31 | |||
| 2022-09-30 | 0.14 | 0.00 | |
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | 0.00 | 0.00 | |
| 2021-09-30 | 0.00 | 0.00 | |
| 2021-06-30 | |||
| 2021-03-31 | 0.80 | -0.15 | 0.18 |
| 2020-12-31 | 0.80 | -0.21 | 0.18 |
| 2020-09-30 | 0.80 | -0.00 | 0.20 |
| 2020-06-30 | 0.78 | -0.02 | 0.22 |
Identifiers and Descriptors
| Central Index Key (CIK) | 14272 |
Industry Groups
| SIC 2834 - Pharmaceutical Preparations |
